Skip to main content

Table 2 Characteristics and dose volume data for patients with a locoregional failure

From: Salivary gland-sparing other than parotid-sparing in definitive head-and-neck intensity-modulated radiotherapy does not seem to jeopardize local control

No. Primary site T stage N stage V95 of the PTV Location of the Vf Vf-V95* (site of failure) Time to recurrence (months)
1 Oropharynx T3 N2b 95% In-field 99% (N) 8
2 Larynx T2 N2c 93% In-field 99% (N) persistence
3 Oral cavity T4 N2c 92% In-field 99% (T) persistence
4 Larynx T3 N2c 95% Marginal 50% (T) 9
5 Oropharynx T4 N3 97% In-field 100% (T + N) 7
6 Oral cavity T4 N0 98% In-field 99% (T) 16
7 Hypopharynx T3 N2c 96% In-field 94% (N) 15
8 Oropharynx T3 N2b 89% In-field 100% (N) 15
9 Oropharynx T3 N1 96% In-field 100% (N) persistence
10 Oral cavity T3 N2a 96% In-field 95% (T + N) 10
11 Larynx T2 N2b 95% In-field 100% (T) 100% (N) persistence
12 Oropharynx T3 N2b 97% In-field 99% (T) 8
13 Hypopharynx T3 N2b 99% In-field 100% (T + N) 9
  1. Abbreviations: Vf failure volume; T Tumor; N Node, * Percentage of Vf covered by 95% of the prescription dose.